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Fifteen years after the discovery of hypocretin/orexin a large body of evidence has been
collected supporting its critical role in the modulation of several regulatory physiological
functions. While reduced levels of hypocretin/orexin were initially associated with
narcolepsy, increased levels have been linked in recent years to pathological states of
hypervigilance and, in particular, to insomnia. The filing to FDA of the dual-activity orexin
receptor antagonist (DORA) suvorexant for the indication of insomnia further corroborates
the robustness of such evidences. However, as excessive vigilance is also typical of
anxiety and panic episodes, as well as of abstinence and craving in substance misuse
disorders. In this review we briefly discuss the evidence supporting the development of
hypocretin/orexin receptor 1 (OX1) antagonists for these indications. Experiments using
the OX1 antagonist SB-334867 and mutant mice have involved the OX1 receptor in
mediating the compulsive reinstatement of drug seeking for ethanol, nicotine, cocaine,
cannabinoids and morphine. More recently, data have been generated with the novel
selective OX1 antagonists GSK1059865 and ACT-335827 on behavioral and cardiovascular
response to stressors and panic-inducing agents in animals. Concluding, while waiting
for pharmacologic data to become available in humans, risks and benefits for the
development of an OX1 receptor antagonist for Binge Eating and Anxiety Disorders are
discussed.
Keywords: drug addiction, relapse, binge eating, repetitive behavior, emotion, OX1 receptor antagonist,
GSK1059865
INTRODUCTION
Hypocretin/orexin is an hypothalamic neuropeptide consisting of
two forms, A and B, containing 33 and 28 amino acids respec-
tively, and binding to two G-protein coupled receptors, OX1 (or
hcrt-1) and OX2 (or hcrt-2) (de Lecea et al., 1998; Sakurai et al.,
1998).
The hypocretin/orexin peptide is produced in a small pop-
ulation of neurons located in the dorsomedial—perifornical
hypothalamic area (DMH/PeF) and in the lateral hypothalamic
nucleus (LH). Positive nerve fibers and terminals can be found
in several areas of the central and peripheral nervous system,
including vagus nerve, spinal cord, brainstem, hypothalamus,
thalamus, limbic system, and some cortical regions (Peyron et al.,
1998; Heinonen et al., 2008). OX/hcrt receptors show a similarly
extended distribution (Marcus et al., 2001), suggesting a poten-
tial relevant role of hypocretins/orexins as regulatory peptides for
several adaptive and limbic system-controlled functions (Johnson
et al., 2012a,b;Mahler et al., 2012; Boutrel et al., 2013; Tsujino and
Sakurai, 2013).
The OX1 receptor contains 425 amino acids while the
OX2 receptor contains 444 amino acids with a sequence sim-
ilarity between the two receptors of 68% (Sakurai et al.,
1998). While both receptors are coupled with Gq-protein,
only the OX1 receptor is additionally coupled with Gs-protein.
Receptor activation increases intracellular calcium levels via a
Gq –dependent phospholipase C (PLC)-mediated increase of
inositol-1,4,5-triphosphate (Lund et al., 2000) and diacylglycerol,
resulting in the activation of the δ form of the protein kinase C,
eventually engaging the ERK phosphorylation pathway (Ekholm
et al., 2007).
OX1 and OX2 receptors are differentially distributed through-
out the mammalian brain (Marcus et al., 2001), matching the
distribution of hypocretin/orexin terminals. Evidence for a func-
tional segregation of the two receptors was recently obtained
using pharmacological magnetic resonance imaging (phMRI)
in rats. The activating effects of amphetamine were differen-
tially attenuated by pre-treatment with the selective OX2 receptor
antagonist JNJ-1037049 or with the novel OX1 receptor antag-
onist GSK1059865: JNJ-1037049 attenuated the amphetamine
effects in frontal cortex and thalamus, areas involved in arousal,
while GSK1059865 reduced the activation in the extended amyg-
dala, BNST and ventral striatum; all brain areas involved in
stress and motivation (Gozzi et al., 2011). These differences in
functional maps, together with differences in behavioral profiles
support a rationale for exploring different indications for novel
therapeutics that selectively target either OX1 or OX2 receptors.
However, while the role of the OX2 receptor in sleep and arousal
is strongly supported by the available experimental evidence
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(Gatfield et al., 2010), the therapeutic potential of selective antag-
onism of the OX1 receptor is still under evaluation (Gotter et al.,
2012).
The better understanding of the biology of the hypocre-
tin/orexin system has promoted drug discovery programs in
several pharmaceutical companies, resulting in a series of patents
and compounds with different selectivity and in vitro character-
istics (Faedo et al., 2012; Lebold et al., 2013). As shown above,
some compounds were used as pharmacologic tools to explore
OX1- and OX2-dependent neurotransmission in vivo. Few com-
pounds were successfully progressed in humans, in particular the
dual OX1-OX2 receptor antagonist (DORA) almorexant (Hoever
et al., 2012), SB-649868 (Bettica et al., 2012), and suvorexant
(Herring et al., 2012). Only suvorexant went successfully through
Phase 3 development and it was filed in USA as new treatment for
insomnia in 2013.
The first pharmacological tool used as OX1 receptor antagonist
was SB-334867 (Jones et al., 2001; Smart et al., 2001). Recently,
other compounds have been proposed: GSK1059865 (Alvaro
et al., 2009; Gozzi et al., 2011), 2,5 di-substituted piperidines
(Jiang et al., 2012) and ACT-335827 (Steiner et al., 2013).
In this review we address the evidence, mostly collected with
pharmacologic tools, for a preferential role of the OX1-mediated
neurotransmission in compulsive behavior, particularly in rela-
tion to addiction and binge eating, and in anxiety.
HYPOCRETIN/OREXIN AND THE OX1 RECEPTOR IN DRUG
ADDICTION-LIKE AND COMPULSIVE EATING BEHAVIORS
Several preclinical findings indicated the involvement of the
hypocretin/orexin system in compulsive and repetitive behav-
ior as well as in the control of goal-oriented behavior. Recent
excellent reviews summaries the evidence collected in more than
hundred articles indicting that the hypocretin/orexin system in
the lateral hypothalamus (Harris et al., 2005) is involved in the
behavioral addiction-like dysregulations associated with exposure
to cocaine, amphetamine, morphine, heroin, nicotine, ethanol
and cannabinoids in rodents (Espana et al., 2011; Mahler et al.,
2012; Boutrel et al., 2013; Flores et al., 2013), as well as in the
excessive intake of palatable food associated with binge eating
(Tsujino and Sakurai, 2013).
Data supporting the hypocretin/orexin involvement in the
effects of addictive drugs was initially obtained in mice car-
rying a null mutation (KO) of the hypocretin/orexin peptide,
showing reduced signs of withdrawal from morphine (Georgescu
et al., 2003). Subsequently, impaired conditioned place pref-
erence for morphine (Narita et al., 2006) and for nicotine
(Plaza-Zabala et al., 2012) was demonstrated in rodents. More
recently, studies in KO mice with deletion of the OX1 recep-
tor showed reduced cocaine and cannabinoid self-administration
and the blockade of reinstatement of drug taking after abstinence
(Hollander et al., 2012; Flores et al., 2013), indicating a criti-
cal role for OX1 receptors in mediating reinstatement of drug
seeking.
In rodents SB-334867, a preferential OX1 receptor antagonist,
reduced sensitization, drug seeking behavior and withdrawal syn-
drome in rodents exposed to ethanol, nicotine, morphine, and
cocaine. These and other findings were extensively described in
recent reviews (Mahler et al., 2012; Boutrel et al., 2013). Of partic-
ular interest is the fact that SB-334867 consistently attenuated the
compulsive behavior associated with the reinstatement of drug
seeking, induced by either acute stress or cues associated pre-
viously with drug taking, a phenomenon observed for ethanol,
nicotine, cocaine, cannabinoids and morphine.
Recently, the highly selective OX1 receptor antagonist GSK
1059865 (5-bromo-N-[(2S,5S)-1-(3-fluoro-2-methoxybenzoyl)-
5-methylpiperidin-2-yl]methyl-pyridin-2-amine) was character-
ized within the GSK collection (Alvaro et al., 2009). GSK1059865
at the dose of 25mg/kg i.p. (estimated to fully occupy the OX1
receptors in the brain of the rat) only marginally modified the
physiological sleep of rats, indicating a weak hypnotic effect
(Gozzi et al., 2011; Piccoli et al., 2012) and confirming difference
vs. OX2 receptor blockade (Mieda et al., 2011). Conversely, at 10
and 30mg/kg i.p. doses, GSK1059865 significantly antagonized
the cocaine effect in a conditioned place-preference paradigm
(Gozzi et al., 2011). These results are in line with the proposed
role of selective OX1 receptor antagonism in preventing relapse
to drug seeking but not inducing sleep.
OX1 receptors were also recently involved in mediating the
binge episodes of compulsive eating (Avena and Bocarsly, 2012),
also defined as “food addiction,” another compulsive behav-
ior increasingly common among obese individuals (Volkow and
Wise, 2005; Pedram et al., 2013). Although it was initially shown
that the acute central administration of orexin-A stimulates
feeding behavior by acting on specific hypothalamic circuits
(Friederich et al., 2013), hypocretin/orexin-induced food intake
appears to be influenced by several other factors, including the
palatability of the food, the energy balance, the level of arousal
and the emotional status (Yamanaka et al., 2003; Zheng et al.,
2007; Choi et al., 2010; Tsujino and Sakurai, 2013). This suggests
that the hypocretin/orexin system can activate more complex
behavioral patterns than the sole increase of food intake (Mahler
et al., 2012). Indeed, recent studies indicate a possible involve-
ment of hypocretin/orexin dysregulation in compulsive intake of
palatable food (Smith and Robbins, 2013).
Compulsive eating can be elicited in rodents by alternating
periods of regular access to food with periods of food restriction
over a few weeks, a specific chronic stressful condition that can
produce binge episodes when a large amount of palatable food
becomes suddenly available. The model was pharmacologically
validated in rats, showing an inhibitory effect of topiramate on
the compulsive food intake (Cifani et al., 2009) similar to that
observed in human binge eaters (McElroy et al., 2003). Although
data regarding the involvement of the hypocretin/orexin pathway
in this experimental procedure of binge eating were not available,
we studied the effect of GSK1059865 as a tool to assess the rel-
evance of the OX1 receptors (Piccoli et al., 2012). Interestingly,
GSK1059865, at the doses of 10 and 30mg/kg, was not able
to inhibit highly palatable food intake in control animals (not
exposed to cyclic food restriction), confirming the minor effect of
OX1 receptor blockade on natural reward when it occurs under
physiological conditions. On the contrary, GSK1059865 potently
inhibited the compulsive eating behavior in rats exposed to
chronic stress/food restriction (Piccoli et al., 2012). Interestingly,
regular food intake was also inhibited by the OX1 antagonist
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SB-334867 in rats genetically prone to obesity but not in con-
trol rats (White et al., 2005). These findings confirmed the role of
the OX1 receptor-mediated transmission in attenuating the exces-
sive drive produced by craving associated to distress that was also
observed with addictive drugs.
Interestingly binge eating was also inhibited by the DORA
SB-649868, but not by the selective OX2 receptor antagonist JNJ-
10397049, suggesting that the effects of SB-649868 are probably
due to the OX1 component of its mechanism of action (Piccoli
et al., 2012). Intriguingly, the lack of effect of almorexant in ani-
mals exposed only to acute stress suggested that the procedure of
alternating periods of food restriction is critical for the engage-
ment of the hypocretin/orexin system in promoting compulsive
eating of highly palatable food (Funabashi et al., 2009; Pankevich
et al., 2010). This observation suggests that in this paradigm
DORA and OX1 antagonists do not work primarily via an anti-
stress effect. This is not surprising, given the complex role of
hypocretin/orexin in the maintenance of energy balance and the
sensitivity of hypocretin/orexin neurons to directly respond to
the changes of circulating glucose levels and to endocrine signals
(Tsujino and Sakurai, 2013).
Overall, the results obtained with GSK1059865 confirm that
selective OX1 receptor antagonism is not directly affecting the
reward pathways involved in hedonic eating, but rather support
a role in the compulsive aspect of food intake, those that prob-
ably account for the development and persistence of abnormal
eating behaviors in binge eaters and, possibly, in bulimic patients.
In addition, these data highlight the need to re-evaluate the puta-
tive OX1 receptor antagonism profile, so far based mostly on
SB-334867 (Haynes et al., 2000), a compound whose selectivity
at high dose and stability have been under discussion (Hollander
et al., 2012; McElhinny et al., 2012).
To date a limited number of human biomarker studies sup-
port a role for the hypocretin/orexin system in the behavioral
dysregulation that characterizes addiction, and none of them
used pharmacologic agents. Changes of hypocretin/orexin levels
in blood were observed in alcoholics during alcohol withdrawal,
showing positive association with distress scores (von der Goltz
et al., 2011), while negative association was observed with crav-
ing scores in abstinent smokers (von der Goltze et al., 2010).
Increased expression of hypocretin/orexin levels was also found in
the in peripheral blood of cigarette smokers and cannabis abusers
(Rotter et al., 2012). While the interpretation of these finding
is still unclear, subjects affected by narcolepsy were studied for
their liability to addiction with the hope to get more informa-
tive results. Accordingly, narcolepsy is commonly associated with
mutations in the hypocretin/orexin gene (Peyron et al., 1998),
resulting in a constitutive deficiency of the peptide, similar to
that obtained in hypocretin/orexin KO mice. Subtle differences
in reward processing and risk-taking behavior were reported in
narcoleptic subjects, but the prevalence of tobacco smoking in
these patients was not different from that of the normal popu-
lation (Bayard and Dauvilliers, 2013). There results can be seen
at variance with evidence of reduced effects of addictive drugs in
hypocretin/orexin KO mice (for review see Mahler et al., 2012;
Boutrel et al., 2013). Interestingly, narcoleptic subjects declared
using cigarette smoking and nicotine patches as self-medication
to reduce sleepiness and increase arousal (Ebben and Krieger,
2012). Altogether, the findings indicate complexity in the rela-
tionship between addictive behaviors and dysfunctional hypocre-
tin/orexin system in humans, supporting the need of additional,
more focused translational studies.
HYPOCRETIN/OREXIN AND THE OX1 RECEPTOR IN ANXIETY
Textbooks of physiology describe the posterior and perifornical
regions of the hypothalamus as the part of the limbic circuit that
controls “fight-or-flight” reactions in response to an imminent
threat (Hess and Akert, 1955). As mentioned above, neurons that
produce hypocretin/oirexin are located in the perifornical region
(Peyron et al., 1998) and project to the majority of the limbic
brain structures involved in the fear, stress and anxiety circuit
(Shin and Liberzon, 2009), suggesting a possible role of hypocre-
tin/orexin in controlling not only wakefulness and arousal, but
also fear, anxiety, and stress responses (Johnson et al., 2012a; Sears
et al., 2013).
This hypothesis was explored over the years and summa-
rized in recent articles and reviews (Bisetti et al., 2006; Mathew
et al., 2008; Johnson et al., 2010, 2012a). In these contributions
interested readers can find the evidence supporting the role of
hypocretin/orexin neurons in orchestrating the autonomic, res-
piratory, cardiovascular and behavioral responses to stressful and
panic-inducing stimuli.
The working hypothesis implies that stressful stimuli (or high
endogenous levels of anxiogenic mediators) would increase the
activity on hypocretin/orexin neurons, which in turn will release
more hypocretin/orexin in their terminal fields located in brain
limbic regions that regulate emotion and stress response. Then
hypocretin/orexin will be shifting the level of activation of the
fear, stress and anxiety circuit toward a higher level of arousal,
which includes vegetative, endocrine and behavioral phenomena
typical of anxiety and panic states. An abnormal persistence of
excessive release of hypocretin/orexin could be seen as a critical
factor in the maintenance of high arousal and anxiety, as well
as a liability to relapse into panic episodes in predisposed indi-
viduals, suggesting a potential critical pathophysiological role for
anxiety.
Data in humans showed an increased release of extracellu-
lar hypocretin/orexin driven by emotional stimuli in the amyg-
dala of subjects suffering from treatment-resistant temporal lobe
epilepsy that were implanted with microdialysis probes (Blouin
et al., 2013). In this study the levels of hypocretin/orexin increased
during wake and decreased during sleep, but the highest peaks
were observed during acute emotional activations of both pos-
itive and negative valence. The amygdala is considered a key
structure for processing salience and negative emotion, which
is associated with pathologic anxiety. In rodents microinjection
of hypocretin/orexin into the amygdala increases anxiety-like
behavior (Avolio et al., 2011). Interestingly, abnormal high lev-
els of hypocretin/orexin were found in the cerebro-spinal fluid
(CSF) of patients with Panic Anxiety Disorders, suggesting a
possible hyperactivity state (Johnson et al., 2010). In another
study increased levels of hypocretin/orexin were measured in the
peripheral blood of subjects with chronic obstructive pulmonary
disorder (COPD), a condition associated with hypercapnia,
acidosis and a 10-fold increased risk of panic attacks (Zhu et al.,
2011).
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Converging findings suggest that the anxiogenic properties
of hypocretin/orexin are primarily mediated by the engagement
of OX1 receptors. In rodents the autonomic and behavioral
responses to stress were attenuated by pre-treatments with OX1
receptor antagonists, such as SB-334867 (Johnson et al., 2010,
2012b), GSK 1034865 (Gozzi et al., 2011) and ACT-335827
(Steiner et al., 2013), or with a DORA, such as almorexant
(Steiner et al., 2012). Significant attenuation of anxiety-like
responses was observed in paradigms including fear conditioning
(Sears et al., 2013; Steiner et al., 2013), panicogenic lactate infu-
sion (Johnson et al., 2010), hypercapnia (Li et al., 2010; Johnson
et al., 2012b), administration of FG-7142 (Johnson et al., 2012a),
high dose nicotine (Plaza-Zabala et al., 2010), and yohimbine
(Richards et al., 2008). Recent evidence using OX1 and OX2
KO mice showed a critical role of OX1 receptors located in the
locus coeruleus in mediating cued fear-conditioning learning and
threat memory formation (Sears et al., 2013; Soya et al., 2013).
Evidence that hypocretin/orexin-containing neurons receive
inputs from other neurons producing the anxiogenic peptide
corticotropin releasing factor (CRF) and that hypocretin/orexin
neurons projects to CRF-rich brain regions suggested the possibil-
ity that these two peptidergic systems are functionally entangled
in the control of the stress response (Ida et al., 2000; Pañeda
et al., 2005). However, if this hypothesis is correct, the anxi-
olytic properties of CRF-1 antagonists (Zorrilla and Koob, 2004)
and those of OX1 antagonists would overlap, showing similar
profiles. Interestingly, a recent study using phMRI in rats sug-
gests that the involvement of CRF-1 and OX1 in stress responses
can be functionally segregated. In this experiment a phMRI
activation brain map was elicited in rats with yohimbine at
doses known to produce anxiogenic effects. Pre-treatments with
either CP-154,526, a selective CRF-1 antagonist (Seymour et al.,
2003), or the selective OX1 receptor antagonist GSK1059865
(Gozzi et al., 2011) were performed. The yohimbine activa-
tion brain map was attenuated by CP-154,526 in the motor,
cingulate, retrosplenial, dorsal prefrontal cortex, dorsal por-
tions of the caudate-putamen, and in the amygdala. Differently,
GSK1059865 attenuated the yohimbine activation map in the
nucleus accumbens, septum, dorsal thalamus, amygdala, ventral
hippocampus, orbitofrontal, prefrontal, insular, cingulate retro-
splenial, and piriform cortex (Gozzi et al., 2013). Overall, the
OX1 receptor antagonist exerted a more extensive effect on the
fear, stress and anxiety circuit than the CRF1 antagonist, attenu-
ating the activations of regions of the dopaminergic mesolimbic
system. In line with the latter observation, a dissociation was
found between the effects of OX1 and CRF-1 antagonists on
the rat mesolimbic dopamine system in stress-induced cocaine
(Wang et al., 2009) and nicotine seeking (Plaza-Zabala et al.,
2012).
Interestingly, in some studies both OX1 antagonists and
DORAs did not show anxiolytic effects in specific behavioral
tests (e.g., the elevated plus maze) (Steiner et al., 2012; Rodgers
et al., 2013). These data are in line with the hypothesis that
hypocretin/orexin receptor antagonists do not alter basal anxi-
ety levels in rodents, but exert anxiolytic-like properties when
anxiety levels are transiently exacerbated by potent stimuli such
as acidosis/hypercapnia.
LIMITATIONS AND CONCLUSION
The rationale for considering OX1 receptors as a possible tar-
get in conditions such as Anxiety Disorders, Drug Addiction,
and Binge Eating was reviewed. Based on the current knowl-
edge on mechanism of action, OX1 receptor antagonists should
have fewer development risks than DORAs. As highlighted by
Scammell and Winrow (2011) and Boutrel et al. (2013) for
DORAs, the chronic simultaneous blockade of both hypocre-
tin/orexin receptors can potentially: (1) induce narcoleptic-like
symptoms, including catalepsy; (2) impair goal oriented decision-
making; (3) reduce pleasure associated with rewarding activities;
(4) induce sedation, sleepiness and impaired coping responses
under acute emergency or stress; (5) impact on basal metabolism
with increased body weight. However, so far the human expe-
rience with the DORAs suvorexant, SB-649868 and almorexant
is very encouraging, showing minimal occurrence of the above
mentioned adverse events and, in particular, no induction of nar-
coleptic eoisodes or impairment of decision making performance
when tested within the dose range currently proposed. However,
more data on larger populations and higher doses are required to
reach a final conclusion.
Interestingly, treatments with selective OX1 antagonists are
not expected to share the same risks of DORAs since only the
OX2 receptor is primarily associated with narcolepsy which was
demonstrated for dogs carrying a disruptive genetic mutation of
this receptor (Wu et al., 2011). The additional potential benefits
of an OX1 antagonist include: (1) A preclinical anxiolytic pro-
file that differentiates it from benzodiazepines, serotonin-uptake
inhibitors, and CRF-1 antagonists; (2) The capacity of reduc-
ing hyper-arousal states associated to acute and severe anxiety
episodes with relevant physical symptoms, such as panic attacks
or withdrawal from addictive drugs; (3) The attenuation of com-
pulsive and repetitive behaviors associated with sensitization,
stress-relieve, or drug seeking; (4) The lack of effects on desire
of natural rewards, and (5) the lack of sleep-inducing effects.
These considerations are based on a limited dataset of pre-
clinical studies, only recently conducted with the new generation
of selective compounds. Chronic dosing studies are missing and
therefore information of long term risks and benefits are not
available yet. In addition, no selective OX1 receptor antagonists
have been tested in humans so far and the translational barrier
is still unclear. However, the promising therapeutic potential in
the modulation of anxiety and compulsive behaviors is stimulat-
ing further basic research and is encouraging active investments
of pharmaceutical companies.
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